Kashiv Pharma Swallows Up Adello Biologics, Becoming Kashiv BioSciences
New Jersey-based Kashiv adds biosimilar assets to its repertoire by acquiring Adello Biologics, becoming, in its own words, a “fully-integrated biosciences company with an expanded and dynamic platform for growth.” Adello’s CEO, Chintu Patel, will lead the combination.
You may also be interested in...
Amneal says it has taken the latest step towards “Amneal 2.0” after completing its deal to acquire Kashiv Specialty Pharmaceuticals.
Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.